FTC Files Amicus Brief in Asthma Inhaler Patent Dispute

Improper Orange Book listings can harm competition by delaying the entry of cheaper generic products, according to the FTC’s brief.

Metadata
Provider: 
FTCFTC
URL: 
https://www.ftc.gov/news-events/news/press-releases/2024/03/ftc-files-amicus-brief-asthma-inhaler-patent-disputehttps://www.ftc.gov/news-events/news/press-releases/2024/03/ftc-files-amicus-brief-asthma-inhaler-patent-dispute
Retrieved on: 
Tuesday, April 2, 2024
Information
Tags: 
The Orange Book, GSK plc, AstraZeneca, District court, Boehringer Ingelheim, Social media, Salbutamol, Policy, News, Blog, Motion, Judgement, Orange Book, Commission, Patent, FDA, Federal Trade Commission, Food, FTC
Geotags: 
NEW YORK
Summary
Key Points: 
  • Improper Orange Book listings can harm competition by delaying the entry of cheaper generic products, according to the FTC’s brief.
  • The FTC’s amicus brief relates to a case brought by Teva against drugmaker Amneal after Amneal sought FDA approval to bring a generic version of asthma inhaler ProAir HFA to market.
  • Teva sued Amneal for patent infringement, arguing that Amneal’s patents infringe on Teva’s ProAir HFA patents.
  • The FTC’s amicus brief was filed in the U.S. District Court for the District of New Jersey.
Copyright: 
2024 FTC. All Rights Reserved.